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Abstract
Background.—Close contacts of persons with pulmonary tuberculosis (TB) have high rates of 
TB disease.
Methods.—We prospectively enrolled TB patients and their close contacts at 9 US/Canadian 
sites. TB patients and contacts were interviewed to identify index patient, contact, and exposure 
risk factors for TB. Contacts were evaluated for latent TB infection (LTBI) and TB, and the 
effectiveness of LTBI treatment for preventing contact TB was examined.
Results.—Among 4490 close contacts, multivariable risk factors for TB were age ≤5 years, US/
Canadian birth, human immunodeficiency virus infection, skin test induration ≥10 mm, shared 
bedroom with an index patient, exposure to more than 1 index patient, and index patient weight 
loss (P < .05 for each). Of 1406 skin test–positive contacts, TB developed in 49 (9.8%) of 446 who 
did not initiate treatment, 8 (1.8%) of 443 who received partial treatment, and 1 (0.2%) of 517 who 
completed treatment (1951, 290, and 31 cases/100 000 person-years, respectively; P < .001). TB 
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was diagnosed in 4.2% of US/Canadian-born compared with 2.3% of foreign-born contacts (P 
= .002), and TB rates for US/Canadian-born and foreign-born contacts who did not initiate 
treatment were 3592 and 811 per 100 000 person-years, respectively (P < .001).
Conclusions.—Treatment for LTBI was highly effective in preventing TB among close contacts 
of infectious TB patients. Several index patient, contact, and exposure characteristics associated 
with increased risk of contact TB were identified. These findings help inform contact 
investigation, LTBI treatment, and other public health prevention efforts.
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Close contacts of pulmonary tuberculosis (TB) patients have high rates of TB disease [1–7]. 
Factors that predispose to TB are incompletely understood.
In the United States, Canada, and most countries with low TB incidence, contact 
investigations are conducted for pulmonary TB patients in order to identify and treat 
secondary cases of active TB disease and latent TB infection (LTBI) among exposed 
contacts, thereby interrupting secondary transmission of Mycobacterium tuberculosis and 
preventing progression from LTBI to TB disease [1, 2, 8, 9]. Understanding TB risk factors 
among exposed contacts is important for determining the optimal timing and expected yield 
of contact investigations, as well as prioritizing public health prevention efforts among 
persons at highest TB risk.
We conducted a prospective study of contact investigations at health departments in the 
United States and Canada. We previously described rates and timing of TB among contacts 
and risk factors for LTBI treatment default [3, 10]. Here, we examine risk factors for TB 
disease in the same contact cohort.
METHODS
We prospectively enrolled culture-confirmed adult TB patients and their close contacts at 9 
US and Canadian sites in the Tuberculosis Epidemiologic Studies Consortium [11]. Close 
contacts were defined as described previously [3]. TB patients were interviewed, and 
contacts were identified, interviewed, and screened for LTBI and TB, then followed for up to 
4 years (final follow-up February 2011) [3].
All health departments defined negative tuberculin skin tests (TSTs) as <5 mm and positive 
TSTs as ≥5 mm induration. Contacts with TB diagnosed >30 days after index case diagnosis 
were considered incident cases, and those diagnosed ≤30 days after index case diagnosis 
were considered coprevalent cases [3].
Univariate analyses were performed on potential index patient, contact, and exposure 
location risk factors for contact TB. We considered variables for multivariable models if 
their univariate P value was < .20 and kept variables with a P value < .05 in the models. 
Survival analysis methods were as previously described [3]. Statistically significant 
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differences were defined as P < .05 using the χ2 or Fisher exact test. SAS software version 
9.2 was used for all analyses [12].
Contacts were categorized as not treated for LTBI if they did not initiate treatment, partially 
treated if they started but did not complete treatment, and completely treated if they 
completed the required duration of treatment for the regimen received. TB rates for each 
treatment category were determined by dividing the total number of TB cases by person-
years of follow-up and compared with the rate for contacts who received no treatment. 
Coprevalent cases were excluded from LTBI treatment analyses. Although several treatment 
regimens were used, most contacts received either isoniazid or rifampin monotherapy.
This study was approved by institutional review boards at the Centers for Disease Control 
and Prevention and all project sites.
RESULTS
Characteristics of the Study Population
Characteristics of the 718 index patients and 4490 close contacts enrolled are included in 
Table 1. Of the index patients, 518 (72%) had positive sputum smears and 286 (40%) had 
cavitation on chest radiograph. Of the contacts, 158 (4%) had TB, 1390 (31%) had LTBI, 
1650 (36%) were TST-negative and free of TB, and 1292 (29%) did not complete TST 
screening. Of 158 TB cases among contacts, 81 were coprevalent and 77 were incident. Of 
the TB cases, 115 (73%) were diagnosed in TST-positive contacts (57 coprevalent and 58 
incident cases), 6 (4%) in TST-negative contacts (3 coprevalent and 3 incident cases), and 37 
(23%) in contacts who did not complete TST screening (21 coprevalent and 16 incident 
cases). A total of 1329 contacts did not complete TST screening (37 with TB and 1292 
without TB).
Risk Factors for TB Among Close Contacts
In univariate analyses for all TB among contacts, risk factors significantly associated with 
TB included contact age ≤5 years, US/Canadian birth, human immunodeficiency virus 
(HIV) test-positive, and skin test induration ≥10 mm; index patient cavitary disease, bilateral 
disease, weight loss, night sweats, and current smoking; and household exposure, shared 
bedroom with the index patient, ≥500 exposure hours, and exposure to more than 1 index 
patient (Table 2).
In univariate analyses for incident TB among contacts, risk factors significantly associated 
with TB included contact age ≤5 years, US/Canadian birth, and skin test induration ≥10 mm; 
index patient bilateral disease, cough ≥3 weeks, and weight loss; and household exposure, 
≥500 exposure hours, and exposure to more than 1 index patient (Table 3). Exposure to an 
index patient with positive sputum smears (P = .061) or cavitation on chest radiograph (P 
= .081) and shared bedroom with an index patient (P = .081) were not significant for 
incident TB cases.
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In analyses including all TB cases or only incident TB cases, the risk of TB was similar for 
nonhousehold contacts and household contacts who did not share a bedroom with the index 
patient.
Univariate analyses of risk factors for coprevalent TB and for incident TB restricted to TST-
positive contacts showed similar findings to those reported above (data not shown).
Effectiveness of LTBI Treatment
Of 3161 contacts who completed TST screening, 1505 (48%) were TST-positive. Of these, 
57 had coprevalent TB and were excluded from LTBI treatment analyses. Of the remaining 
1448 contacts, 517 (37%) completed LTBI treatment, 443 (32%) received a partial treatment 
course, and 446 (32%) did not initiate treatment; 42 contacts with missing treatment 
information (16 with TB and 26 without TB) were excluded from analysis.
Incident TB was diagnosed in 49 (9.8%) of 446 contacts who did not initiate treatment, 8 
(1.8%) of 443 who received partial treatment, and 1 (0.2%) of 517 who completed treatment 
(1951, 290, and 31 cases/100 000 person-years of exposure, respectively; P < .001 for 
complete vs no treatment and for partial vs no treatment; Table 4).
Contact Birthplace and TB
TB was diagnosed in 4.2% of US/Canadian-born contacts compared with 2.3% of foreign-
born contacts (P = .002; Table 2).
Of 446 TST-positive contacts who did not initiate LTBI treatment (Table 4), 197 were US/
Canadian-born and 249 were foreign-born. A total of 37 TB cases occurred among US/
Canadian-born contacts (37/197 = 18.8%) vs 12 TB cases among foreign-born contacts 
(12/249 = 4.8%; P < .001). TB rates for US/Canadian-born and foreign-born contacts who 
did not initiate treatment were 3592 and 811 per 100 000 person-years, respectively (P 
< .001).
Disease-free survival was significantly lower for US/Canadian-born contacts compared with 
foreign-born contacts (Figure 1).
US/Canadian and foreign-born contacts were exposed to index patients with similar smear 
and chest radiograph findings and were equally likely to initiate and complete LTBI 
treatment (data not shown). Compared with foreign-born contacts, US/Canadian-born 
contacts were more likely to be aged ≤5 years (14% vs 2%; P < .001).
Multivariable Analyses
In multivariable analysis (Table 5), risk factors for all cases of TB included contact age ≤5 
years, US/Canadian birth, HIV test-positive, and skin test size ≥10 mm; exposure to an index 
case with weight loss; exposure to more than 1 index case; and shared bedroom with the 
index case. Risk factors for incident TB included contact age ≤5 years, US/Canadian birth, 
and skin test size ≥10 mm; exposure to an index case with weight loss; and exposure to more 
than 1 index case. After adjustment for LTBI treatment, risk factors for incident TB included 
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contact age ≤5 years, US/Canadian birth, exposure to an index case with weight loss, and 
exposure to more than 1 index case.
DISCUSSION
In our study, 3.5% of all close contacts and 7.6% of TST-positive contacts of culture-
confirmed pulmonary TB patients were diagnosed with TB, with a large burden of both 
coprevalent and incident TB among contacts. Our study identifies factors associated with 
increased exposure to infectious TB (shared bedroom and exposure to more than 1 index 
patient), skin test induration ≥10 mm, contact age ≤5 years, and US/Canadian birth as 
factors associated with TB among contacts. We observed that completion of LTBI treatment 
was strongly associated with lack of progression to TB disease among exposed contacts. 
These findings help inform health department decisions on prioritizing contact investigation, 
LTBI treatment, and other public health prevention efforts to interrupt transmission. These 
results are also important for infectious disease physicians and general practitioners, the 
people who often first diagnose active TB and have a relationship with the patient.
In a recent report, we demonstrated that 51% of all TB cases among contacts that occurred 
over a 5-year period were diagnosed before, at the same time, or within 30 days after the 
index TB patient was diagnosed [3]. Through analysis of epidemiologic data collected for 
the same close contact cohort, we have identified independent risk factors for TB. Because 
the direction of transmission cannot always be established with certainty when index 
patients and contacts are diagnosed with TB in rapid succession, we did separate analyses of 
epidemiologic risk factors for all TB cases and incident cases. Our findings have 
implications for active case finding in high-burden settings as well as secondary prevention 
of transmission in countries with a low TB burden, such as the United States and Canada.
Skin test reaction size was strongly correlated in multivariable analyses with TB both among 
all contacts and among incident cases. Increased skin test size is not well characterized as a 
TB risk factor and is not part of algorithms currently used to prioritize contact investigations 
in the United States and Canada [1]. Our findings, together with additional observations 
[13–16], suggest that skin test size could be a useful predictor of TB among exposed 
contacts and merits consideration in developing future algorithms.
Household contacts are traditionally thought to be at the highest TB risk [1, 2]. In our study, 
household contacts who shared a bedroom with the index patient had high TB risk; however, 
those who did not had risk similar to that of nonhousehold contacts. The correlation of 
sharing a bedroom with an index patient and higher TB risk likely reflects both more close 
contact, with more frequent shared airspace and increased risk of sharing infectious aerosols, 
and greater duration of contact, with shared airspace at night and during the day. The fact 
that nonhousehold contacts were at equal risk of TB as household contacts who did not share 
the index case bedroom underscores the importance of a concentric circle approach to 
contact investigations, which incorporates all spheres of daily activities rather than 
exclusively the household [1, 2, 17].
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We evaluated exposure duration, location, and closeness as well as the number of infectious 
patients to whom a contact was exposed in an effort to examine the relationship between 
exposure and TB risk. It is plausible that greater duration or closeness of exposure would 
result in higher disease risk by increasing the likelihood that contacts share infectious 
aerosols with an index patient as well as serving as a marker for an increased exposure 
“dose” of M. tuberculosis. Indeed, our findings that greater hours of exposure to an index 
patient, greater closeness of exposure through sharing a bedroom, and exposure to more than 
1 index patient are all correlated with increased TB risk are consistent with this hypothesis. 
Although the latter 2 factors were independent predictors of TB, an association for exposure 
hours was not demonstrated in multivariate analysis. A likely explanation is that household 
contacts who shared a bedroom with the index patient or were exposed to more than 1 index 
patient were many of the same persons with a higher number of exposure hours. Thus, the 
likely colinearity of the different exposure measures resulted in only 2 identified as 
independent predictors of TB.
Young children had the highest TB risk, which is consistent with several previous studies [4, 
8, 18, 19]. In multivariable analysis, young age was a predictor of both coprevalent and 
incident TB. Thus, children had both rapid development of disease and high overall TB risk. 
This underscores the importance of prioritizing rapid screening, diagnosis of TB and LTBI, 
and initiation of treatment for this high-risk group.
US/Canadian birth was associated with increased TB risk, with the rate among persons who 
did not initiate LTBI treatment more than 4-fold per 100 000 person-years higher than for 
foreign-born contacts. This finding was unexpected since TB case rates in the United States 
are 15 times higher among foreign-born than US-born residents [20], and more than 70% of 
all TB cases reported in the US are foreign-born [20]. US/Canadian-born and foreign-born 
contacts in our study were exposed to index patients with a similar clinical profile and were 
equally likely to initiate and complete LTBI treatment. Thus, it is unlikely that our findings 
could be the result of differences in exposure or treatment. A higher proportion of US/
Canadian-born contacts were aged ≤5 years, which could contribute to our findings. 
However, age and US/Canadian birth were both independent predictors of TB risk, so age 
differences alone do not explain this finding. Further, the inclusion of several sites with a 
predominance of US-born TB patients could help explain the larger proportion of US-born 
TB patients in the study compared with national reporting but does not explain the 
differences in TB risk between US/Canadian-born and foreign-born contacts that we 
observed. A possible explanation is that foreign-born contacts have a higher likelihood of 
previous TB exposure (and previous infection or disease) [8, 9, 21–26] than contacts born in 
low-incidence areas such as the United States and Canada and are thus at lower risk of 
developing disease from the recent exposure [27]. These findings can inform TB prevention 
strategies in the United States and Canada, including modeling and cost analyses for TB 
elimination.
HIV infection is the strongest known predictor of TB [5, 8, 15, 17, 28]. Consistent with this, 
HIV was an independent predictor of TB in multivariate analysis of all TB cases among 
contacts in our study. However, neither index case positive smear nor cavitary chest 
radiograph, traditionally recognized risk factors for transmission [1, 2, 29, 30], were 
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identified in multivariable analysis as risk factors for contact TB in our study. Positive 
sputum smear, cavitation, bilateral disease, cough, and smoking could be risk factors for 
transmission but not risk factors for progression to TB disease, or not independent risk 
factors after other markers of the extent of TB infection are included. Mycobacterium 
tuberculosis transmission and progression to TB disease are separate biologic processes 
[31]. Thus, it is not surprising that the risk factors for transmission and progression to TB 
disease were different.
Fifty years ago, the lifetime TB risk in individuals with LTBI was estimated to be 5%–10%, 
with half of all cases identified within 2 years following exposure [8, 9]. Our recent previous 
report provides evidence that the vast majority of secondary cases identified within 5 years 
after exposure occur within the first year, with the highest rates in the first 3 months [3]. 
Thus, recently exposed close contacts with a new LTBI diagnosis are at high risk of rapidly 
progressing to TB disease. LTBI treatment has been associated with a substantial decrease in 
TB disease risk [8, 9]. In an earlier analysis of preliminary data from our cohort, LTBI 
treatment with isoniazid for 6 or more months was associated with lower TB rates compared 
with shorter treatment [10]. In the current analysis, which excludes coprevalent TB cases, 
limits analyses to the first contact exposure, and includes several different treatment 
regimens, contacts who completed LTBI treatment had the lowest TB rates, those with 
partial treatment had somewhat higher rates, and untreated contacts had markedly higher TB 
rates than contacts with either partial or complete treatment. Moreover, we demonstrated that 
even a partial LTBI treatment course had some effectiveness in preventing TB among 
recently exposed close contacts. These findings emphasize the importance of rapid initiation 
and thorough conduct of contact investigation, not only as an important means for 
identifying persons with active disease but also to diagnose LTBI and initiate treatment, thus 
preventing progression to active TB disease.
Although our recent report suggests that fewer TB cases among contacts can be prevented 
than previously anticipated [3], data in the current report demonstrate that LTBI treatment 
was still highly effective in preventing TB, with a reduction in TB rates per person-year of 
85% for partial treatment and 98% for complete treatment. These findings contrast with 2 
reports in which LTBI treatment was not effective [5] or of lower efficacy [4] among 
contacts. A likely reason for this difference is that in the other studies, treatment appears to 
have been initiated later (up to 180 days in Amsterdam [4] and approximately 270 days in 
New York [5] compared with an average of less than 60 days in our study [32]). Given the 
rapid decline in TB diagnosis rates among contacts beyond the first several months after 
index case diagnosis demonstrated in our recent report [3], the efficacy of LTBI treatment 
would be expected to decrease progressively the later it is initiated since fewer and fewer 
cases can be prevented. This underscores the importance of evaluating contacts and initiating 
LTBI treatment as soon as possible in order to have the biggest impact on disease 
prevention. The effectiveness of even a partial LTBI treatment course is also noteworthy and 
reemphasizes the benefit of initiating treatment for all exposed contacts with newly 
documented LTBI [1].
In our study, nearly one-third of contacts did not complete skin testing, and this group had a 
5-fold higher TB risk than skin test–negative contacts. Many, but not all, of the contacts with 
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TB and no skin test results had coprevalent TB and may not have completed screening 
because of a concurrent TB diagnosis. Nevertheless, the large number of contacts who did 
not complete screening emphasizes the importance of developing strategies to improve 
testing of contacts as well as acceptance and completion of treatment in infected contacts [9, 
10]. Engaging providers outside of health departments is one potential approach to consider 
that this study can help to inform.
Study limitations include incomplete HIV testing data for many contacts, incomplete TST 
screening for some contacts, and the possibility that skin test size could have contributed to 
TB diagnosis for some coprevalent cases. The large number of contacts with TB included in 
our study, complete LTBI treatment data for most contacts, the prospective and protocol-
driven nature of data collection, and collection of information on numerous epidemiologic 
factors, including systematic interviewing to quantify hours of exposure, were study 
strengths.
In conclusion, our study provides important new information on risk factors for TB disease 
and the effectiveness of LTBI treatment in contacts with recent exposure to infectious TB 
patients. Our findings underscore the importance of contact investigation as a mechanism for 
identifying and treating new cases of active TB among contacts and emphasizes the 
importance of prompt screening and LTBI treatment. These findings have important 
implications for tuberculosis prevention efforts [1, 33, 34].
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Figure 1. 
Disease-free survival for 4490 contacts (158 with and 4332 without tuberculosis), by 
birthplace (United States/Canada shown in red, other countries shown in blue).
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Table 1.
Clinical and Demographic Characteristics of Index Tuberculosis Patients and Close Contacts
No. (%)
Index Cases Contacts
Characteristic (n = 718) (n = 4490)
Total 718 4490
Age (y)
 0–14 0 (0) 879 (20)
 15–44 393 (55) 2288 (51)
 ≥45 325 (45) 1173 (26)
 Unknown 0 (0) 150 (3)
Sex, Male 440 (61) 2301 (51)
Race/Ethnicity
 White 96 (13) 548 (12)
 Black 360 (50) 2234 (50)
 Asian/Pacific Islander 81 (11) 266 (6)
 Hispanic 146 (20) 1064 (24)
 Other 35 (5) 378 (8)
Birthplace, United States/Canada 436 (61) 2946 (66)
Age (y) (y (irthplace
 United States/Canada
  0–5 … 420 (14)
  6–14 … 359 (12)
  15–44 … 1279 (43)
  ≥45 … 862 (29)
  Unknown … 26 (1)
 Other
  0–5 … 32 (2)
  6–14 … 68 (4)
  15–44 … 1009 (65)
  ≥45 … 311 (20)
  Unknown … 124 (8)
Place of contact household … 2794 (62)
Diagnostic outcome
 TB … 158 (4)
 LTBI … 1390 (31)
 No LTBI or TB … 1650 (36)
 No TST result … 1067 (24)
 Not eligi(le for testinga … 225 (5)
TST result
 Positive … 1505 (34)
 Negative … 1656 (37)
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No. (%)
Index Cases Contacts
Characteristic (n = 718) (n = 4490)
 Otherb … 1329 (30)
Abbreviations: LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test.
aA total of 225 contacts were not eligible for TST screening due to prior positive TST or TB.
bA total of 1329 contacts did not complete TST screening (1292 contacts without TB and 37 contacts with TB).
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nd
er,
 
w
ith
 T
ST
-
po
sit
iv
e 
n
o
 tr
ea
tm
en
t a
s 
th
e 
re
fe
re
nt
 g
ro
up
. F
o
r 
th
is 
m
od
el
, t
he
 la
st 
fa
ct
or
s 
re
m
ov
ed
 b
y 
ba
ck
w
ar
d 
el
im
in
at
io
n 
w
er
e 
to
ta
l h
ou
rs
 o
f e
x
po
su
re
 >
50
0 
(P
 
=
 .
08
) a
nd
 in
de
x
 c
as
e 
co
u
gh
 fo
r >
3 
w
ee
ks
 (P
 
=
 .
15
).
b U
ne
sti
m
at
ed
 a
s a
 re
su
lt 
of
 0
 in
ci
de
nt
 c
as
es
 fo
r c
on
ta
ct
s w
ith
 sk
in
 te
st 
siz
e 
5–
9 
m
m
.
c F
o
r 
sk
in
 te
sts
, n
o 
sk
in
 te
st 
or
 m
iss
in
g 
m
ill
im
et
er
 re
ad
in
g 
w
as
 in
cl
ud
ed
 a
s a
 se
pa
ra
te
 te
rm
 fo
r t
he
 a
na
ly
sis
 o
f a
ll 
TB
 c
as
es
 b
u
t c
od
ed
 a
s m
iss
in
g 
fo
r t
he
 2
 in
ci
de
nt
 T
B 
m
od
el
s.
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